Servier has announced the completion of its acquisition of Day One Biopharmaceuticals, which is valued at roughly $2.5 billion. It represents a key milestone...
Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential first-in-disease treatment for Fragile X syndrome (FXS), the leading...
